

NGS And Metagenomics In The Human Microbiome Therapeutics Market Cause Great Developments In Growth

The Business Research Company's Human Microbiome Therapeutics Market – Opportunities And Strategies – Global Forecast To 2030

LONDON, GREATER LONDON, UK, December 8, 2021 /EINPresswire.com/ -- Technology is expected to be a continued driver of market growth during this period. Markets such as this one will benefit from the greater



efficiencies offered by developments in this area. Technological advances in next-generation sequencing and metagenomics have increased the feasibility of analyzing the entire human microbiome therapeutics. These advances have made it possible to culture the human microbiota, isolate, and identify the anaerobes. Besides, the application of cutting-edge technologies, including the anaerobic co-culture system, metagenomics, transcriptomics and proteomics, is providing major insights into the complexity of relationships between the human microbiome therapeutics and host health and diseases. These technological advances will drive the market for human microbiome therapeutics going forward.

TBRC's holiday sale has begun with discounts on ALL market research reports! <u>Grab your deal</u> now.

Companies in the <u>human microbiome therapeutics market</u> and research institutes are increasing the number of pipeline studies to develop anti-viral drugs for treating many disease conditions. Companies have also started investing in startups and other early-stage companies to develop pipelines for treating different diseases. In June 2020, Debiopharm, a Switzerland-based biopharmaceutical company announced its research collaboration with Takeda Pharmaceuticals, to develop human microbiome therapeutics therapeutics to treat gastrointestinal disorders.

The global human microbiome therapeutics market size is expected to reach a value of nearly \$148.60 million in 2025, having increased at a compound annual growth rate (CAGR) of 21.9% since 2023. The human microbiome therapeutics market is expected to increase from \$148.60

million in 2025 to \$400.00 million in 2030 having increasing at growth rate of 21.9%. Growth is forecast period is expected to drive by increase in funding, increase in prevalence of chronic diseases and technological advances.

Read More On The Global Human Microbiome Therapeutics Market Report: https://www.thebusinessresearchcompany.com/report/human-microbiome-therapeutics-market

Major players covered in the global human microbiome therapeutics market are Seres Therapeutics, Assembly Biosciences, Enterome Bioscience, Vedanta BioSciences, Second Genome Inc.

TBRC's human microbiome therapeutics market report can be segmented by disease into infectious diseases, gastrointestinal disorders, metabolic disorders, cancers, other diseases, by sequencing technology type into targeted gene, RNA, whole-genome shotgun (WGS), others type.

Human Microbiome Therapeutics Market - By Disease (Infectious Diseases, Gastrointestinal Disorders, Metabolic Disorders, Cancers), By Sequencing Technology Type (Targeted Gene, RNA, Whole-Genome Shotgun (WGS)) And By Region, Opportunities And Strategies – Global Forecast To 2030 is one of a series of new reports from The Business Research Company that provides human microbiome therapeutics market overview, forecast human microbiome therapeutics market size and growth for the whole market, human microbiome therapeutics market segments, and geographies, human microbiome therapeutics market trends, human microbiome therapeutics market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request For A Sample Of The Global Human Microbiome Therapeutics Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=3526&type=smp

Here Is A List Of Similar Reports By The Business Research Company:

Microbiome Global Market Report 2021 - By Type (Fecal Microbiota Transplantation (FMT), Microbiome Drugs), By Application (Inflammatory Bowel Disease, Diabetes, Multiple Sclerosis, Rheumatoid Arthritis), By Technology (Genomics, Proteomics, Metabolomics), COVID-19 Growth And Change

https://www.thebusinessresearchcompany.com/report/microbiome-market-global-report-2020-30-covid-19-growth-and-change

Microbiome Therapeutics Global Market Report 2020 - By Product (Probiotics, Prebiotics, Symbiotics), By Application (Inflammatory Bowel Disease, Diabetes, Multiple Sclerosis, Rheumatoid Arthritis), By Distribution Channel (Hospital Pharmacies, Drug stores, Retail Pharmacies, E-commerce stores)

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Proteomics Market 2021 - By Component (Reagents, Instruments, Software), By Type (Protein Microarrays, Spectroscopy, X-ray Crystallography, Chromatography, Electrophoresis, Surface Plasmon Resonance, Protein Fractionation), And By Region, Opportunities And Strategies - Global Forecast To 2030

https://www.thebusinessresearchcompany.com/report/proteomics-market

Interested to know more about <u>The Business Research Company?</u>

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at https://www.thebusinessresearch.company.com/about-the-business-research-company.aspx

Or get a quick glimpse of our services here: https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293

The Business Research Company

Email: info@tbrc.info

Follow us on LinkedIn: https://bit.ly/3b7850r Follow us on Twitter: https://bit.ly/3b1rmjS Check out our Blog: https://blog.tbrc.info/

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter

Twitter LinkedIn EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2021 IPD Group, Inc. All Right Reserved.